Analyst Price Targets — IART
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 28, 2026 10:33 am | — | UBS | $19.00 | $19.53 | TheFly | Integra LifeSciences initiated with a Neutral at UBS |
| July 16, 2026 2:05 pm | — | Truist Financial | $19.00 | $19.75 | TheFly | Integra LifeSciences price target raised to $19 from $14 at Truist |
| July 8, 2026 8:33 pm | — | BMO Capital | $19.00 | $17.30 | TheFly | BMO starts 'show-me story' Integra LifeSciences with a Market Perform |
| June 18, 2026 11:50 am | — | Argus Research | $25.00 | $17.20 | TheFly | Integra LifeSciences upgraded to Buy from Hold at Argus |
| April 15, 2026 12:28 pm | Richard Newitter | Truist Financial | $12.00 | $11.01 | TheFly | Integra LifeSciences price target lowered to $12 from $13 at Truist |
| October 15, 2025 12:34 pm | — | Truist Financial | $15.00 | $14.76 | TheFly | Integra LifeSciences price target raised to $15 from $13 at Truist |
| October 7, 2024 5:33 am | Ryan Zimmerman | BTIG | $20.00 | $17.43 | StreetInsider | BTIG Upgrades Integra LifeSciences (IART) to Neutral |
| July 30, 2024 8:59 am | Richard Newitter | Truist Financial | $26.00 | $24.59 | TheFly | Integra LifeSciences price target lowered to $26 from $32 at Truist |
| July 30, 2024 3:24 am | Joanne Wuensch | Citigroup | $23.00 | $25.42 | StreetInsider | Citi Downgrades Integra LifeSciences (IART) to Sell |
| July 29, 2024 4:12 pm | Ryan Zimmerman | BTIG | $22.00 | $25.42 | TheFly | Integra LifeSciences downgraded to Sell from Neutral at BTIG |
Latest News for IART
Integra LifeSciences Holdings is a turnaround story, maintaining a BUY rating after a strong 2Q26 earnings beat and margin expansion. IART's specialty surgery segment led revenue, while tissue reconstruction saw declines offset by a successful PriMatrix relaunch and upcoming SurgiMend reintroduction. Management targets leverage reduction to 2.5–3.5x by end-2026, prioritizing debt repayment as operating cash flow…
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.